Cargando…
Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment
BACKGROUND: The aim of this study was to assess the long-term clinical tolerance and cardiac safety during trastuzumab treatment for patients diagnosed as having breast cancer with human epidermal growth factor receptor 2 (HER2) overexpression. MATERIAL/METHODS: A total 105 female cases diagnosed as...
Autores principales: | Sun, Yong, Li, Tao, Zhang, Yuanpeng, Zhang, Qiwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198746/ https://www.ncbi.nlm.nih.gov/pubmed/28000658 http://dx.doi.org/10.12659/MSM.898807 |
Ejemplares similares
-
Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction
por: Nowsheen, Somaira, et al.
Publicado: (2018) -
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
por: Levicki, Rea, et al.
Publicado: (2023) -
Does defibrillation threshold increase as left ventricular ejection fraction decreases?
por: Val-Mejias, Jesus E., et al.
Publicado: (2010) -
Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021) -
Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients
por: Nousiainen, T, et al.
Publicado: (2002)